Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + capecitabine for advanced breast cancer
ChiCTR-PRNC-13003611Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Sep 2013
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of gemcitabine and capecitabine in breast cancer, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Gene mutations, Time to progression and 3 more. Started Sep 2013; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR-PRNC-13003611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-PRNC-13003611.